Please login to the form below
Summit appoints Pfizer/Bayer veteran as CMO
David Roblin to lead development of therapies for Duchenne muscular dystrophy and C.difficile
Industry veteran Dr David Roblin has joined the Oxford, UK-based drug development and discovery company Summit as its chief medical officer.
Dr Roblin has years of senior research experience at major pharma firms, including serving as head of research, site director and chief medical officer for Europe R&D during a spell with Pfizer.
He was also head of ant-infectives at Bayer, where he led the development of several antiobiotics, including Avelox (moxifloxacin) and Cipro (ciprofloxacin).
This experience in anti-infectives will prove useful at Summit, with the company's research efforts including the development of treatments for C difficile infection in addition to potential thereapies for Duchenne muscular dystrophy.
"David brings considerable expertise in all aspects of drug development having been instrumental in the successful development of a number of important medicines,” said Summit's CEO Glyn Edwards.
“As our Duchenne muscular dystrophy and C difficile infection drug programmes go through patient clinical trials, David will make a major contribution to their successful development."
Subscribe to our email news alerts
- Top 10 benefits of virtual advisory boards: Save Time and Resources
- NIHR launches new framework to highlight health progress outcomes
- Johns Hopkins and National Cancer Unit develop new genetic risk-scoring method for major diseases
- UKHSA secures UK-based vaccine deal for future influenza pandemics
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments
- Landscape review reveals £1.1bn of UK funding for rare diseases
No results were found
PMHub
Impetus Digital
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
